ANEB
NASDAQAnebulo Pharmaceuticals Inc.
Price$0.37+0.00 (+0.00%)
2026-03-092026-06-10
News · 26 weeks190%
2025-12-142026-06-07
Mix090d
No activity.
Latest news
25 items- SECSEC Form 15-12G filed by Anebulo Pharmaceuticals Inc.15-12G - Anebulo Pharmaceuticals, Inc. (0001815974) (Filer)
- SECSEC Form 25 filed by Anebulo Pharmaceuticals Inc.25 - Anebulo Pharmaceuticals, Inc. (0001815974) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Anebulo Pharmaceuticals Inc.SCHEDULE 13G/A - Anebulo Pharmaceuticals, Inc. (0001815974) (Subject)
- SECSEC Form 10-Q filed by Anebulo Pharmaceuticals Inc.10-Q - Anebulo Pharmaceuticals, Inc. (0001815974) (Filer)
- SECAnebulo Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Anebulo Pharmaceuticals, Inc. (0001815974) (Filer)
- PRAnebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2026 Financial Results and Recent UpdatesAnebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the "Company" or "Anebulo"), today announced financial results for the three months ended December 31, 2025, and recent updates. Second Quarter Fiscal Year 2026 and Subsequent Highlights: On February 6, 2026, Anebulo announced that the Company's board of directors (the "Board") approved the voluntary delisting of the Company's common stock from The Nasdaq Capital Market ("Nasdaq") and the subsequent voluntary deregistration of its common stock with the U.S. Securities and Exchange Commission ("SEC") in order to t
- SECAnebulo Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits8-K - Anebulo Pharmaceuticals, Inc. (0001815974) (Filer)
- PRAnebulo Pharmaceuticals Announces Intention to Voluntarily Delist from Nasdaq and Deregister with SECAnebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the "Company" or "Anebulo"), today announced that the Company's board of directors (the "Board") has approved the voluntary delisting of the Company's common stock from The Nasdaq Capital Market ("Nasdaq") and the subsequent voluntary deregistration of its common stock with the U.S. Securities and Exchange Commission ("SEC") in order to terminate and suspend its reporting obligations under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Simultaneously with this announcement, Anebulo notified Na
- SECAmendment: SEC Form SC TO-I/A filed by Anebulo Pharmaceuticals Inc.SC TO-I/A - Anebulo Pharmaceuticals, Inc. (0001815974) (Subject)
- SECAnebulo Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Anebulo Pharmaceuticals, Inc. (0001815974) (Filer)
- PRAnebulo Pharmaceuticals Announces Final Results of Tender OfferAnebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the "Company" or "Anebulo"), today announced the final results of its voluntary self-tender offer to purchase 300,000 shares of its common stock, par value $0.001 per share ("Common Stock"), which expired one minute after 11:59 p.m., New York City time, on January 26, 2026. Based on the final count by Broadridge Corporate Issuer Solutions, LLC, the depositary for the tender offer, a total of 4,907,881 shares of Common Stock were properly tendered and not properly withdrawn. The tender offer was oversubscribed. In
- SECAmendment: SEC Form SC TO-I/A filed by Anebulo Pharmaceuticals Inc.SC TO-I/A - Anebulo Pharmaceuticals, Inc. (0001815974) (Subject)
- SECAnebulo Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Anebulo Pharmaceuticals, Inc. (0001815974) (Filer)
- PRAnebulo Pharmaceuticals Announces Preliminary Results of Tender OfferAnebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the "Company" or "Anebulo"), today announced the preliminary results of its voluntary self-tender offer to purchase 300,000 shares of its common stock, par value $0.001 per share ("Common Stock"), which expired one minute after 11:59 p.m., New York City time, on January 26, 2026. Based on the preliminary count by Broadridge Corporate Issuer Solutions, LLC, the depositary for the tender offer, a total of 4,897,188 shares of Common Stock were properly tendered and not properly withdrawn, excluding 10,868 shares that w
- SECAmendment: SEC Form SC TO-I/A filed by Anebulo Pharmaceuticals Inc.SC TO-I/A - Anebulo Pharmaceuticals, Inc. (0001815974) (Subject)
- SECSEC Form SC TO-I filed by Anebulo Pharmaceuticals Inc.SC TO-I - Anebulo Pharmaceuticals, Inc. (0001815974) (Subject)
- SECSEC Form SC TO-I filed by Anebulo Pharmaceuticals Inc.SC TO-I - Anebulo Pharmaceuticals, Inc. (0001815974) (Subject)
- SECAnebulo Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Anebulo Pharmaceuticals, Inc. (0001815974) (Filer)
- PRAnebulo Pharmaceuticals Announces Its Intent to Commence a Self Tender OfferAnebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the "Company" or "Anebulo"), today announced that the Board of Directors has decided to commence a cash tender offer as part of its plan to "go private" in lieu of the previously announced reverse stock split at a ratio of not less than 1-for-2,500 and not greater than 1-for-7,500. Voluntary Self Tender consists of acquiring up to 300,000 shares at $3.50 price per share While the Board of Directors believed that the reverse stock split transaction was in the best interest of the Company and its stockholders at t
- SECSEC Form 10-Q filed by Anebulo Pharmaceuticals Inc.10-Q - Anebulo Pharmaceuticals, Inc. (0001815974) (Filer)
- SECAnebulo Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Anebulo Pharmaceuticals, Inc. (0001815974) (Filer)
- PRAnebulo Pharmaceuticals Reports First Quarter Fiscal Year 2026 Financial Results and Recent UpdatesAnebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the "Company" or "Anebulo"), today announced financial results for the three months ended September 30, 2025, and recent updates. First Quarter Fiscal Year 2026 and Subsequent Highlights: On September 25, 2025, Anebulo announced the first subjects dosed in a Phase 1 single ascending dose ("SAD") study of an intravenous (IV) formulation of its lead drug candidate selonabant. Selonabant is under development for treatment of acute cannabis-induced toxicity in children. The study will investigate the safety, tolerabi
- SECAmendment: SEC Form SC 13E3/A filed by Anebulo Pharmaceuticals Inc.SC 13E3/A - Anebulo Pharmaceuticals, Inc. (0001815974) (Subject)
- SECSEC Form PRER14A filed by Anebulo Pharmaceuticals Inc.PRER14A - Anebulo Pharmaceuticals, Inc. (0001815974) (Filer)
- SECSEC Form 10-K filed by Anebulo Pharmaceuticals Inc.10-K - Anebulo Pharmaceuticals, Inc. (0001815974) (Filer)
ANEB FAQ
6 questionsWhat does Anebulo Pharmaceuticals Inc. do?
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing treatments for patients suffering from cannabinoid overdose and addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.Where does ANEB stock trade?
Anebulo Pharmaceuticals Inc. (ANEB) is listed on NASDAQ.What sector and industry is ANEB in?
Anebulo Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Anebulo Pharmaceuticals Inc. go public?
Anebulo Pharmaceuticals Inc. (ANEB) completed its IPO in 2021.What companies are similar to ANEB?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ANEB side-by-side with any of them on Quantisnow.How can I track ANEB on Quantisnow?
Quantisnow aggregates Anebulo Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ANEB to receive live email and push alerts on every new disclosure.